TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8494580

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (0.14 mg/nostril b.i.d.)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Budesonide nasal aerosol (0.05 mg/nostril b.i.d.)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray
Number of subjects: 193

Group type: COMPARATOR
Intervention: Budesonide nasal aerosol
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray and Budesonide nasal aerosol
Number of subjects: 193
Study: 3320788

Group type: COMPARATOR
Intervention: Carvedilol, a new beta-adrenergic blocking agent with direct vasodilator activity, administered orally.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study: 31753737

Group type: EXPERIMENTAL
Intervention: Interim methadone with patient navigation (IM + PN)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Interim methadone (IM)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Enhanced treatment-as-usual (ETAU)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Combined IM groups (IM + PN and IM)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: All groups (IM + PN, IM, ETAU)
Number of subjects: 225
Study: 30085876

Group type: EXPERIMENTAL
Intervention: Enamel deproteinization, acid etching, bonding agent application, and pit & fissure sealant placement
Number of subjects: 206

Group type: COMPARATOR
Intervention: Acid etching followed by pit & fissure sealant application only
Number of subjects: 206
Study: 27714541

Group type: EXPERIMENTAL
Intervention: Cabozantinib (100 mg daily during a 12-week lead-in stage)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cabozantinib (after randomization)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cabozantinib (during lead-in stage)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (after randomization)
Number of subjects: 45
Study: 24990101

Group type: EXPERIMENTAL
Intervention: Full portion aerated drink (1,000 ml, 190 kcal)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Half portion aerated drink (500 ml, 95 kcal)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Full portion liquid drink (325 ml, 190 kcal)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Half portion liquid drink (162 ml, 95 kcal)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Water saturated with N2 O
Number of subjects: 47

Group type: COMPARATOR
Intervention: Water saturated with CO2
Number of subjects: 47
Study: 22515902

Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MTA Plus
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Biodentine and MTA Plus
Number of subjects: 30
Study: 20684675

Group type: EXPERIMENTAL
Intervention: Hypothermia (32-33°C)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Normothermia
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (diagnostic lumbar puncture to rule out infection)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both hypothermia and normothermia groups
Number of subjects: 34
Study: 18201301

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT‐A) injections into the submandibular and parotid glands; 25 units of BoNT‐A into each gland.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group received no treatment.
Number of subjects: 48
Study: 15989411

Group type: EXPERIMENTAL
Intervention: DHEA 50 mg daily
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) 0.625 mg daily
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: DHEA 50 mg + CEE 0.625 mg daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 12558724

Group type: EXPERIMENTAL
Intervention: Predictive instrument based on functional status at admission, cognitive function, and social support.
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: PHD scores of 0 or 1
Number of subjects: 781
Study: 10494116

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of 15 mg trospium chloride in 40 ml saline
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of 30 mg trospium chloride in 40 ml saline
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of trospium chloride (both dosages)
Number of subjects: 6
Study: 8702086

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (conjugated estrogens, 0.625 mg/d and medroxyprogesterone, 5 mg/d)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 1751030

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 6751514

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery followed by cis-platinum containing combination chemotherapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 39
Study: 30060292

Group type: EXPERIMENTAL
Intervention: Pfannenstiel incision
Number of subjects: 91

Group type: COMPARATOR
Intervention: Vertical skin incision
Number of subjects: 91
Study: 29017511

Group type: EXPERIMENTAL
Intervention: Mechanical wrist traction (12 treatments, twice a week for 6 weeks)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 181

Group type: COMPARATOR
Intervention: Mechanical wrist traction and Care as usual
Number of subjects: 181
Study: 25943680

Group type: EXPERIMENTAL
Intervention: H + H (32 ± 1 °C, 50% RH, 16.6% O2 normobaric hypoxia)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: H + H
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: RPEWU
Number of subjects: 18
Study: 24368400

Group type: EXPERIMENTAL
Intervention: Everolimus 5 mg/day plus erlotinib 150 mg/day
Number of subjects: 133

Group type: COMPARATOR
Intervention: Erlotinib 150 mg/day
Number of subjects: 133
Study: 22553307

Group type: EXPERIMENTAL
Intervention: CABG with mitral surgery
Number of subjects: 1212

Group type: COMPARATOR
Intervention: CABG without mitral surgery
Number of subjects: 1212

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 1212

Group type: COMPARATOR
Intervention: CABG with mitral surgery versus CABG alone
Number of subjects: 1212
Study: 20014909

Group type: EXPERIMENTAL
Intervention: Atomoxetine (40 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 17585060

Group type: EXPERIMENTAL
Intervention: A2/A2 genotype (n = 872)
Number of subjects: 1611

Group type: COMPARATOR
Intervention: A1/A1 or A1/A2 genotype (n = 486)
Number of subjects: 1611
Study: 14739125

Group type: EXPERIMENTAL
Intervention: Torcetrapib 10 mg daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Torcetrapib 30 mg daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Torcetrapib 60 mg daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Torcetrapib 120 mg daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Torcetrapib 120 mg twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11408427

Group type: EXPERIMENTAL
Intervention: Acute heavy resistance exercise (AHRE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study: 9403145

Group type: EXPERIMENTAL
Intervention: Gamblers (N = 15)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Spouses (N = 15)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (N = 15)
Number of subjects: 15
Study: 8094169

Group type: EXPERIMENTAL
Intervention: Duplex scanning
Number of subjects: 52

Group type: COMPARATOR
Intervention: Descending phlebography
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Ascending phlebography
Number of subjects: 52
Study: 3113329

Group type: EXPERIMENTAL
Intervention: Cefadroxil (75 children), given once daily
Number of subjects: 150

Group type: COMPARATOR
Intervention: Phenoxymethyl penicillin (75 children), given three times daily
Number of subjects: 150
Study: 31975475

Group type: EXPERIMENTAL
Intervention: Topical selenium (Se)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic selenium (Se)
Number of subjects: 0
Study: 30760296

Group type: EXPERIMENTAL
Intervention: Behavioural nudge intervention with improved positioning and attractive labelling of fruit and vegetables in school cafeterias over a three-week period.
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control condition (no intervention).
Number of subjects: 176
Study: 28363480

Group type: EXPERIMENTAL
Intervention: 16 mg/day TRF-budesonide
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 8 mg/day TRF-budesonide
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 25692789

Group type: EXPERIMENTAL
Intervention: Cutting diathermy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 66
Study: 24191330

Group type: EXPERIMENTAL
Intervention: Generic formulation of flurbiprofen (tablet Flurso)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Branded product of flurbiprofen (tablet Ansaid)
Number of subjects: 22
Study: 21193552

Group type: EXPERIMENTAL
Intervention: IV ketamine
Number of subjects: 60

Group type: COMPARATOR
Intervention: SC ketamine
Number of subjects: 60
Study: 19825056

Group type: EXPERIMENTAL
Intervention: McGrath videolaryngoscope
Number of subjects: 25

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 25
Study: 19126934

Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 0
Study: 14747426

Group type: EXPERIMENTAL
Intervention: d‐MPH administered in a fasting state
Number of subjects: 0

Group type: COMPARATOR
Intervention: d‐MPH administered after a high‐fat breakfast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d‐MPH administered with food
Number of subjects: 0
Study: 12745746

Group type: EXPERIMENTAL
Intervention: 1.5% glycine infusion at 0.5 ml/kg/min for 30 min
Number of subjects: 12

Group type: COMPARATOR
Intervention: 3% mannitol infusion (control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1.5% glycine infusion
Number of subjects: 12
Study: 9825681

Group type: EXPERIMENTAL
Intervention: Single surgeon continuity schedule
Number of subjects: 214

Group type: COMPARATOR
Intervention: Staff of surgeons continuity schedule
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Both schedules
Number of subjects: 214
Study: 8085509

Group type: EXPERIMENTAL
Intervention: Home Treatment Team (HTT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional community services (Control)
Number of subjects: 54
Study: 2502795

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 4 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1099489

Group type: EXPERIMENTAL
Intervention: Ketoprofen (Orudis)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Phenylbutazone
Number of subjects: 14
Study: 30346099

Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sitagliptin 200 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 28321497

Group type: EXPERIMENTAL
Intervention: Intra-procedural myocardial deformation imaging in the cardiac catheter laboratory (CLab)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Two-step determination of myocardial viability by cardiovascular magnetic resonance (CMR)
Number of subjects: 123
Study: 25451704

Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin
Number of subjects: 1390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1390
Study: 23881910

Group type: EXPERIMENTAL
Intervention: Maraviroc (7 days administration)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (alcohol)
Number of subjects: 10
Study: 21420908

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 5927

Group type: EXPERIMENTAL
Intervention: SOD (Selective Oropharyngeal Decontamination)
Number of subjects: 5927

Group type: EXPERIMENTAL
Intervention: SDD (Selective Digestive Tract Decontamination)
Number of subjects: 5927

Group type: EXPERIMENTAL
Intervention: SDD
Number of subjects: 5927

Group type: EXPERIMENTAL
Intervention: SOD
Number of subjects: 5927
Study: 19673941

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg/day for 12 weeks
Number of subjects: 365

Group type: COMPARATOR
Intervention: Control group (246 subjects without CHD)
Number of subjects: 365
Study: 17909199

Group type: EXPERIMENTAL
Intervention: Bevacizumab + Erlotinib
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bevacizumab + Chemotherapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 120
Study: 15529490

Group type: EXPERIMENTAL
Intervention: Extraction of the deciduous canine only
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Extraction of the deciduous canine with cervical pull headgear
Number of subjects: 46

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 46
Study: 11189801

Group type: EXPERIMENTAL
Intervention: 10% price reduction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25% price reduction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50% price reduction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Promotional signage (low-fat label plus promotional sign)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Promotional signage (low-fat label)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No promotional signage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Equal price
Number of subjects: 0
Study: 9777793

Group type: EXPERIMENTAL
Intervention: Tazarotene-UVB treatment (tazarotene 0.1% gel once daily for 2 weeks followed by tazarotene plus UVB therapy 3 times per week for 10 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: UVB therapy alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: UVB therapy plus vehicle gel
Number of subjects: 0
Study: 7817163

Group type: EXPERIMENTAL
Intervention: 2 ml (0.1 mg) fentanyl intravenously
Number of subjects: 56

Group type: COMPARATOR
Intervention: 2 ml saline intravenously
Number of subjects: 56
Study: 2802431

Group type: EXPERIMENTAL
Intervention: Home-monitor group (n = 23)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Clinic group (n = 23)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Home-monitor group
Number of subjects: 50
Study: 1106278

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Prednisone only
Number of subjects: 38
Study: 30056747

Group type: EXPERIMENTAL
Intervention: Melodic Intonation Therapy (12 sessions over six weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waiting list control (no treatment initially)
Number of subjects: 20
Study: 28654363

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (n = 19,541)
Number of subjects: 48835

Group type: COMPARATOR
Intervention: Usual diet comparison (n = 29,294)
Number of subjects: 48835
Study: 26790209

Group type: EXPERIMENTAL
Intervention: Deep needling
Number of subjects: 50

Group type: COMPARATOR
Intervention: Shallow needling
Number of subjects: 50
Study: 23940216

Group type: EXPERIMENTAL
Intervention: cediranib (30 mg) monotherapy
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: cediranib (20 mg) plus lomustine (110 mg/m(2))
Number of subjects: 325

Group type: COMPARATOR
Intervention: lomustine (110 mg/m(2)) plus placebo
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: cediranib (30 mg) monotherapy and cediranib (20 mg) plus lomustine
Number of subjects: 325
Study: 16627149

Group type: EXPERIMENTAL
Intervention: Mail administration of SF-36 and Oxford Hip questionnaires
Number of subjects: 99

Group type: COMPARATOR
Intervention: Interview administration of SF-36 and Oxford Hip questionnaires
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Comorbidity analysis
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Age analysis
Number of subjects: 99
Study: 14510037

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) + Contingency Management (CM)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) + Noncontingency Management (NCM)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo + Contingency Management (CM)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo + Noncontingency Management (NCM)
Number of subjects: 149
Study: 10467973

Group type: EXPERIMENTAL
Intervention: Lithium augmentation
Number of subjects: 76
Study: 8605789

Group type: EXPERIMENTAL
Intervention: Flumazenil (maximum of 1 mg in double-blind phase, up to 2.5 mg in open phase)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.7 +/- 0.3 mg)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 110
Study: 1874931

Group type: EXPERIMENTAL
Intervention: 1000 mg elemental calcium/day
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: 2000 mg elemental calcium/day
Number of subjects: 295

Group type: COMPARATOR
Intervention: Control group (no calcium supplementation)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (both doses)
Number of subjects: 295
Study: 7045659

Group type: EXPERIMENTAL
Intervention: Dipyridamole plus aspirin
Number of subjects: 407

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 407
Study: 31371315

Group type: EXPERIMENTAL
Intervention: Low-dose dacarbazine (DTIC) administered at 850 mg/m2 intravenously on days 1 and 28, and interferon‐alpha‐2b (IFN‐α‐2b) administered at 3 million units three times a week subcutaneously for 24 weeks beginning at week 9.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Low-dose dacarbazine (DTIC) and interferon‐alpha‐2b (IFN‐α‐2b)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Observation group (eligible but not enrolled patients)
Number of subjects: 33
Study: 30149135

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (2 × 10^8 CFU, twice daily during antibiotic treatment)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 27935085

Group type: COMPARATOR
Intervention: 70% 1-repetition maximum (1RM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 90% 1-repetition maximum (1RM)
Number of subjects: 10
Study: 26455249

Group type: EXPERIMENTAL
Intervention: Counselling group (written instruction + monthly counselling)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Counselling group
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (written instruction only)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 240
Study: 23791497

Group type: EXPERIMENTAL
Intervention: Conventional + modified ultrafiltration (MUF) (CM) group
Number of subjects: 65

Group type: COMPARATOR
Intervention: Prime + zero‐balanced + MUF (PZM) group
Number of subjects: 65
Study: 21545190

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection of methylprednisolone acetate 40 mg/mL with 0.8 mL lidocaine plus injection of 1 mL hyaluronic acid 0.8% 10 days later (n=15; group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open surgical release of the first annular pulley (n=15; group B)
Number of subjects: 30
Study: 18467278

Group type: EXPERIMENTAL
Intervention: Interventions for antisocial personality disorder (ASPD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correctional practices
Number of subjects: 0
Study: 16634495

Group type: EXPERIMENTAL
Intervention: Early loading of implants (< or = 14 days postimplantation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard loading of implants (3 to 4 months postimplantation)
Number of subjects: 24
Study: 14663805

Group type: EXPERIMENTAL
Intervention: Sonography
Number of subjects: 47

Group type: COMPARATOR
Intervention: Axiography
Number of subjects: 47
Study: 10966244

Group type: EXPERIMENTAL
Intervention: Quantitative cultures obtained by bronchoscopic or nonbronchoscopic techniques (Group A)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Nonquantitative tracheal aspirates cultures based on clinical judgment (Group B)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Days of mechanical ventilation
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: ICU stay
Number of subjects: 91
Study: 8695094

Group type: EXPERIMENTAL
Intervention: Epidural PCA (EPCA) with sufentanil: 0.3 microgram/kg bolus followed by 8 micrograms/hr infusion plus epidural PCA boluses of 4 micrograms every 6 min as needed
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: i.v. PCA with sufentanil: 0.3 microgram/kg bolus followed by 8 micrograms/hr infusion plus IV PCA boluses of 4 micrograms every 6 min as needed
Number of subjects: 29

Group type: COMPARATOR
Intervention: i.v. PCA with morphine: 0.1 mg/kg bolus followed by 0.5 mg/hr infusion plus i.v. PCA boluses of 1 mg every 6 min as needed
Number of subjects: 29
Study: 1739528

Group type: EXPERIMENTAL
Intervention: DDD mode
Number of subjects: 16

Group type: COMPARATOR
Intervention: VVI mode
Number of subjects: 16

Group type: COMPARATOR
Intervention: DDI mode
Number of subjects: 16
Study: 6686121

Group type: EXPERIMENTAL
Intervention: Unsupervised walking-programme
Number of subjects: 108
Study: 31129600

Group type: EXPERIMENTAL
Intervention: Fitbit and up to six telephone health-coaching sessions
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 86
Study: 29432857

Group type: EXPERIMENTAL
Intervention: intensive antiretroviral treatment strategy
Number of subjects: 368

Group type: COMPARATOR
Intervention: standard antiretroviral treatment strategy
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: interruption of treatment
Number of subjects: 368

Group type: COMPARATOR
Intervention: continuation of treatment
Number of subjects: 368
Study: 26829102

Group type: EXPERIMENTAL
Intervention: Microneedles (MNs) of 500μm or 750μm length, in arrays containing 10 or 50 MNs
Number of subjects: 28
Study: 24589573

Group type: EXPERIMENTAL
Intervention: Corneal debridement using a sterile #15 blade on a Bard-Parker handle
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conjunctival swabs only (Control Group)
Number of subjects: 120